ACTA1 and systemic sclerosis: Maurizio Cutolo and colleagues found that Nintedanib inhibits the conversion of circulating fibrocytes to myofibroblasts and their pro-fibrotic activity in SSc patients, significantly downregulating the gene and protein expression of αSMA, S100A4, COL1, and FN in these cells [91].